Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model

• Published in: World journal of gastroenterology : WJG Vol. 23; no. 25; pp. 4559 - 4568
• Main Authors: Shin, Seung Kak, Cho, Jae Hee, Kim, Eui Joo, Kim, Eun-Kyung, Park, Dong Kyun, Kwon, Kwang An, Chung, Jun-Won, Kim, Kyoung Oh, Kim, Yoon Jae
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 07.07.2017
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Antioxidants - pharmacology; Antioxidants - therapeutic use; Apoptosis - drug effects; Basic Study; Cell Line; Colitis, Ulcerative - chemically induced; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - pathology; Colon - metabolism; Colon - pathology; Dextran Sulfate - toxicity; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Inflammation Mediators - metabolism; Male; Mice; Mice, Inbred C57BL; Oxidative Stress - drug effects; Rats; Reactive Oxygen Species - metabolism; Rosuvastatin Calcium - pharmacology; Rosuvastatin Calcium - therapeutic use; Tumor Necrosis Factor-alpha - metabolism; Inflammatory bowel disease; Oxidative stress; Rosuvastatin; Apoptosis
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v23.i25.4559

To evaluate the anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium (DSS)-induced colitis model. An acute colitis mouse model was induced by oral administration of 5% DSS in the drinking water for 7 d. In the treated group, rosuvastatin (0.3 mg/kg per day) was administered orally before and after DSS administration for 21 d. On day 21, mice were sacrificed and the colons were removed for macroscopic examination, histology, and Western blot analysis. In the study, IEC-6 cells were stimulated with 50 ng/mL tumor necrosis factor (TNF)-α and then treated with or without rosuvastatin (2 μmol/L). The levels of reactive oxygen species (ROS), inflammatory mediators, and apoptotic markers were measured. In DSS-induced colitis mice, rosuvastatin treatment significantly reduced the disease activity index and histological damage score compared to untreated mice ( < 0.05). Rosuvastatin also attenuated the DSS-induced increase of 8-hydroxy-2'-deoxyguanosine and NADPH oxidase-1 expression in colon tissue. Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels. The increased levels of cleaved caspase-3, caspase-7, and poly (ADP-ribose) polymerase in the DSS group were attenuated by rosuvastatin treatment. , rosuvastatin significantly reduced the production of ROS, inflammatory mediators and apoptotic markers in TNF-α-treated IEC-6 cells ( < 0.05). Rosuvastatin had the antioxidant, anti-inflammatory and anti-apoptotic effects in DSS-induced colitis model. Therefore, it might be a candidate anti-inflammatory drug in patients with inflammatory bowel disease.